Sirt1-Positive Lymphocytes in Acute Cellular Cardiac Allograft Rejection: Contributor to Pathogenesis and a Therapeutic Target

ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs
Kerry J WelshRobert E Brown

Abstract

Cardiac allograft rejection remains a problem, despite advances with immunosuppressants. Understanding the mechanisms behind rejection is essential for developing targeted therapies. The goal of this investigation is to explore Sirtuin 1 (Sirt1) as a therapeutic target for cardiac allograft rejection. Thirteen endomyocardial biopsy specimens with acute cellular rejection (grade 2R or 3R) were selected. CD3, CD4, CD8, CD20, CD68, T-cell intracytoplasmic antigen (TIA-1), and Sirt1 expressions were determined by immunohistochemical stains. Comparison of Sirt1 expression was made with 10 cases of grade 0R and grade 1R. Quantitative image analysis was performed. There were 2 cases of grade 3R and 11 cases of grade 2R acute cellular rejection. Sirtuin 1 expression was present in the majority of mononuclear cells (median percentage, 73.5; interquartile range, 51.2-100%); staining was also observed in cardiomyocytes. Twelve of the 13 cases (92.3%) had an elevated CD8/FoxP3 ratio, coinciding with acute cellular rejection. Sirtuin 1 expression in the nuclei of FoxP3+ cells can lead to deacetylation and inactivation of FoxP3 rendering the T-suppressor cells inactive and promoting acute cellular rejection. The use of a Sirt1 inhibitor may ...Continue Reading

References

Mar 8, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrew BushellKathryn Wood
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Kevin KellyVictoria M Richon
Oct 26, 2005·Nature Immunology·Karsten KretschmerHarald von Boehmer
Mar 7, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Pierre-Yves MantelCarsten B Schmidt-Weber
Jun 20, 2006·Immunity·Casey T WeaverKenneth M Murphy
Feb 9, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·F VeroneseR B Colvin
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Bin LiMark I Greene
Apr 21, 2007·Circulation Research·Ralph R AlcendorJunichi Sadoshima
Jun 19, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·T DeuseB A Reitz
Jun 19, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·W LiJ D Perkins
Apr 11, 2009·Cellular Immunology·Julie L LucasRobert P Numerof
Jan 5, 2011·Molecular and Cellular Biology·Ulf H BeierWayne W Hancock
Feb 1, 2011·Journal of Molecular and Cellular Cardiology·Nagalingam R SundaresanMahesh P Gupta
Feb 9, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hye-Sook KwonMelanie Ott
Mar 23, 2012·Journal of Bioenergetics and Biomembranes·Belma TuranGuy Vassort
Aug 28, 2012·Cellular & Molecular Immunology·Xin ZhangQuan-Xing Wang
Mar 9, 2013·Science·Basil P HubbardDavid A Sinclair
Aug 6, 2013·Transplantation·Xin ZhangQuan-Xing Wang
Dec 3, 2014·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Renee FrankPriti Lal
Jun 17, 2015·Clinical and Experimental Immunology·M SabbatiniG Terrazzano

❮ Previous
Next ❯

Citations

Nov 26, 2016·Progress in Transplantation : Official Publication, North American Transplant Coordinators Organization ... [et Al.]·Lola XieIndranee Rajapreyar
Jul 30, 2019·Frontiers in Endocrinology·Jonathan L Warren, Nancie J MacIver

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.